Advantage Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Advantage Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$12K	Hold	45	–	–	0.01%	619
2019 Q2	$14K	Sell	45 -22	-33%	-$7.32K	0.01%	607
2019 Q1	$28K	Sell	67 -5	-7%	-$2.06K	0.02%	456
2018 Q4	$27K	Buy	72 +25	+53%	+$9.15K	0.02%	460
2018 Q3	$19K	Buy	47 +25	+114%	+$9.52K	0.01%	586
2018 Q2	$8K	Sell	22 -6	-21%	-$1.88K	0.01%	690
2018 Q1	$10K	Buy	28 +6	+27%	+$2.09K	﹤0.01%	681
2017 Q4	$8K	Hold	22	–	–	﹤0.01%	738
2017 Q3	$10K	Hold	22	–	–	﹤0.01%	693
2017 Q2	$11K	Hold	22	–	–	﹤0.01%	688
2017 Q1	$9K	Hold	22	–	–	﹤0.01%	706
2016 Q4	$8K	Hold	22	–	–	﹤0.01%	680
2016 Q3	$9K	Sell	22 -127	-85%	-$50.9K	﹤0.01%	641
2016 Q2	$52K	Buy	149 +9	+6%	+$3.47K	0.02%	339
2016 Q1	$50K	Buy	140 +118	+536%	+$48.6K	0.02%	333
2015 Q4	$12K	Hold	22	–	–	0.01%	539
2015 Q3	$10K	Hold	22	–	–	0.01%	542
2015 Q2	$11K	Hold	22	–	–	0.01%	576
2015 Q1	$10K	Hold	22	–	–	0.01%	590
2014 Q4	$9K	Buy	+22	New	+$8.65K	0.01%	542

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Advantage Investment Management's REGN Position: Q3 2019 in Review

Advantage Investment Management held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2019 at 45 shares worth $12K. The position accounts for 0.01% of the portfolio, ranked #619.

Advantage Investment Management first reported a position in REGN in Q4 2014 and has held it in 20 quarters since. The position peaked at $52K in Q2 2016. 632 funds tracked by Wall St. Rank hold REGN as of Q3 2019.

Advantage Investment Management held 45 shares of Regeneron Pharmaceuticals worth $12K as of Q3 2019.
Advantage Investment Management left its Regeneron Pharmaceuticals share count unchanged in Q3 2019.
Regeneron Pharmaceuticals made up 0.01% of Advantage Investment Management's portfolio in Q3 2019, its #619 holding.
Advantage Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
Advantage Investment Management's Regeneron Pharmaceuticals position peaked at $52K in Q2 2016.
632 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.